文献速递主动脉疾病

腹主动脉瘤腔内修复术后一年内II型内漏消除的相关因素

Factors associated with elimination of type II endoleak during the first year after endovascular aneurysm repair.
PubMed 文献 · J Vasc Surg · 2019-05-18

这项两中心回顾性研究纳入2006至2017年接受EVAR的患者,分析术后1个月CTA存在II型内漏者至12个月时内漏消除与持续的相关因素。825例中140例(17%)有II型内漏,41%消除;术中髂内动脉闭塞与内漏持续直接相关,他汀治疗和瘤囊回缩与消除相关。

要点

  • EVAR术后1个月存在II型内漏的患者中,约41%在12个月内消除。
  • 术中髂内动脉闭塞是II型内漏持续的独立相关因素。
  • 他汀治疗和瘤囊回缩与II型内漏消除相关。

核心结论

  • 术中髂内动脉闭塞是EVAR术后第一年内II型内漏持续的唯一相关因素。
  • 他汀治疗可能对术后第一年II型内漏消除有积极作用。
  • II型内漏消除者瘤囊更易回缩。

研究设计与样本

  • 两中心回顾性研究,纳入2006至2017年接受EVAR的患者。
  • 825例患者中140例(17%)在术后1个月CTA存在II型内漏,平均年龄71.7±8.5岁,94%为男性。
  • 按12个月CTA时II型内漏消除(58例,41%)或持续(82例,59%)分组比较。

主要发现

  • 术前CTA存在腔内血栓者比例在消除组为100%,持续组为67%(P = .001)。
  • 腔内血栓呈环形模式者在消除组为44%,持续组为24%(P = .01)。
  • 12个月CTA时平均瘤囊回缩在消除组为-3±4 mm,持续组为0.55±3 mm(P = .000)。
  • 多因素分析显示II型内漏持续与术中髂内动脉闭塞直接相关(OR 0.232,95%CI 0.06-0.86,P = .03),与他汀治疗(OR 2.6,95%CI 1.01-6.8,P = .047)和瘤囊回缩(OR 1.24,95%CI 1.11-1.39,P = .001)呈 inverse 关联。
  • 肠系膜下动脉和腰动脉的解剖特征及骨盆动脉指数与II型内漏持续无关。

临床怎么用

  • EVAR术中应关注髂内动脉闭塞对II型内漏持续的影响。
  • 对术后存在II型内漏的患者,可考虑评估他汀治疗状态。
  • 随访中瘤囊回缩情况有助于判断II型内漏的转归。

局限性

  • 回顾性研究设计。
  • 仅纳入两个中心的数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The natural history of endoleak type II (ET II) after endovascular aneurysm repair (EVAR) is still debatable. The aim of this study was to examine the presence of preoperative and postoperative factors associated with persistence of ET II during the initial 12-month follow-up period. METHODS: A two-center retrospective study including patients subjected to EVAR from 2006 to 2017 was undertaken. Patients with ET II at 1-month computed tomography angiography (CTA) were categorized into two groups, resolution (group 1) vs persistence (group 2) of ET II at 12-month CTA. Preoperative demographics, comorbidities, aneurysm anatomic details, and pelvic artery index were assessed. Intraoperative details were also recorded. RESULTS: Of 825 patients, 140 (17%) patients (mean age, 71.7 ± 8.5 years; 94% male) presented with ET II at 1-month CTA. Group 1 included 58 patients (41%) and group 2, 82 patients (59%). The anatomic characteristics of the inferior mesenteric artery and lumbar arteries and the pelvic artery indices were not associated with ET II persistence. All patients in group 1 had presence of intraluminal thrombus (ILT) on preoperative CTA (group 1, 100%; group 2, 67%; P = .001), and the circular pattern of ILT was more common in group 1 (group 1, 44%; group 2, 24%; P = .01). At 12-month CTA, the mean sac regression was higher in group 1 (group 1, -3 ± 4 mm; group 2, 0.55 ± 3 mm; P = .000). After multivariate analysis, persistence of ET II was directly associated only with intraoperative internal iliac occlusion (odds ratio [OR], 0.232; 95% confidence interval [CI], 0.06-0.86; P = .03) and inversely with statin therapy (OR, 2.6; 95% CI, 1.01- 6.8; P = .047) and sac regression (OR, 1.24; 95% CI, 1.11-1.39; P = .001). CONCLUSIONS: Induced occlusion of the internal iliac artery during EVAR was the only factor associated with persistence of ET II during the first year after EVAR. The presence and pattern of ILT may play a role in ET II persistence, whereas the number of patent infrarenal aortic branches and their diameter as well as the pelvic artery indices were not associated with ET II. The use of statins may have a positive effect on ET II resolution during the first postoperative year. Sac diameter is more likely to regress in patients with ET II resolution.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Spanos K, Nana P, Kouvelos G, et al. Factors associated with elimination of type II endoleak during the first year after endovascular aneurysm repair. J Vasc Surg. 2019. PMID: 31113721. doi:10.1016/j.jvs.2019.01.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。